Total Payments
$75,523
2024 Payments
$7,431
Companies
11
Transactions
85
Payment Breakdown by Category
Consulting$46,258 (61.2%)
Other$18,250 (24.2%)
Travel$7,575 (10.0%)
Food & Beverage$2,024 (2.7%)
Research$1,417 (1.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $46,258 | 31 | 61.2% |
| Honoraria | $15,250 | 3 | 20.2% |
| Travel and Lodging | $7,575 | 21 | 10.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,000 | 1 | 4.0% |
| Food and Beverage | $2,024 | 23 | 2.7% |
| Unspecified | $1,417 | 6 | 1.9% |
Payments by Type
General
$74,106
79 transactions
Research
$1,417
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Sage Therapeutics, Inc. | $17,038 | 21 | $0 (2022) |
| Jazz Pharmaceuticals Inc. | $10,558 | 17 | $0 (2020) |
| LivaNova USA, Inc. | $9,570 | 7 | $0 (2023) |
| Alkermes, Inc. | $9,413 | 11 | $0 (2019) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $7,406 | 7 | $0 (2024) |
| Boehringer Ingelheim International GmbH | $6,720 | 5 | $0 (2024) |
| Angelini Pharma Inc. | $5,500 | 1 | $0 (2020) |
| Allergan, Inc. | $4,650 | 6 | $0 (2021) |
| H. Lundbeck A S | $3,227 | 3 | $0 (2017) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,417 | 6 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $7,431 | 8 | Boehringer Ingelheim Pharmaceuticals, Inc. ($5,331) |
| 2023 | $9,990 | 8 | LivaNova USA, Inc. ($9,570) |
| 2022 | $8,225 | 5 | Boehringer Ingelheim International GmbH ($4,200) |
| 2021 | $6,570 | 10 | Sage Therapeutics, Inc. ($5,070) |
| 2020 | $10,629 | 13 | Angelini Pharma Inc. ($5,500) |
| 2019 | $14,850 | 23 | Sage Therapeutics, Inc. ($7,678) |
| 2018 | $13,622 | 14 | Alkermes, Inc. ($8,316) |
| 2017 | $4,207 | 4 | H. Lundbeck A S ($3,227) |
All Payment Transactions
85 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/02/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,895.00 | General |
| 07/02/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $140.00 | General |
| 07/02/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $35.00 | General |
| 05/30/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $167.11 | General |
| 05/29/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $73.25 | General |
| 05/29/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $20.86 | General |
| 04/17/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $1,260.00 | General |
| 03/01/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $840.00 | General |
| 10/12/2023 | LivaNova USA, Inc. | VNS THERAPY SYMMETRY MODEL 8103 GENERATOR (Device) | Travel and Lodging | Cash or cash equivalent | $331.91 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/05/2023 | LivaNova USA, Inc. | VNS THERAPY SYMMETRY MODEL 8103 GENERATOR (Device) | Honoraria | Cash or cash equivalent | $6,750.00 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/05/2023 | LivaNova USA, Inc. | VNS THERAPY SYMMETRY MODEL 8103 GENERATOR (Device) | Food and Beverage | In-kind items and services | $483.88 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/05/2023 | LivaNova USA, Inc. | VNS THERAPY SYMMETRY MODEL 8103 GENERATOR (Device) | Travel and Lodging | Cash or cash equivalent | $334.96 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/30/2023 | LivaNova USA, Inc. | VNS THERAPY SYMMETRY MODEL 8103 GENERATOR (Device) | Travel and Lodging | Cash or cash equivalent | $554.00 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/29/2023 | LivaNova USA, Inc. | VNS THERAPY SYMMETRY MODEL 8103 GENERATOR (Device) | Travel and Lodging | Cash or cash equivalent | $487.90 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/15/2023 | LivaNova USA, Inc. | VNS THERAPY SYMMETRY MODEL 8103 GENERATOR (Device) | Travel and Lodging | Cash or cash equivalent | $627.54 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 07/27/2023 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $420.00 | General |
| 12/08/2022 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $1,680.00 | General |
| 11/10/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,075.00 | General |
| 08/09/2022 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $2,520.00 | General |
| 05/04/2022 | Sage Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,560.00 | General |
| 02/17/2022 | Sage Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $390.00 | General |
| 10/01/2021 | Sage Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,560.00 | General |
| 09/07/2021 | Sage Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $390.00 | General |
| 07/13/2021 | Sage Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,170.00 | General |
| 06/22/2021 | Sage Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $390.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN TREATMENT OF ADULTS WITH PTSD | Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,417 | 6 |
About Dr. Dan Iosifescu, MD
Dr. Dan Iosifescu, MD is a Psychiatry healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/09/2005. The National Provider Identifier (NPI) number assigned to this provider is 1831170687.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Dan Iosifescu, MD has received a total of $75,523 in payments from pharmaceutical and medical device companies, with $7,431 received in 2024. These payments were reported across 85 transactions from 11 companies. The most common payment nature is "Consulting Fee" ($46,258).
Ad
Practice Information
- Specialty Psychiatry
- Location Boston, MA
- Active Since 11/09/2005
- Last Updated 07/08/2007
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1831170687
Products in Payments
- VNS THERAPY SYMMETRY MODEL 8103 GENERATOR (Device) $9,570
- SUNOSI (Drug) $7,422
- REXULTI (Drug) $4,644
- VRAYLAR (Drug) $1,500
- LATUDA (Drug) $23.92
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Boston
Dr. Maurizio Fava, Md, MD
Psychiatry — Payments: $248,730
Psychiatry $248,730
Dr. George Papakostas, Md, MD
Psychiatry — Payments: $190,290
Psychiatry $190,290
Dr. Robert Birnbaum, Md, Phd, MD, PHD
Psychiatry — Payments: $182,500
Psychiatry $182,500
Dr. Andrew Nierenberg, Md, MD
Psychiatry — Payments: $165,058
Psychiatry $165,058
Dyanna Domilici, M.d, M.D
Psychiatry — Payments: $91,278
Psychiatry $91,278
Dr. Lee Goldstein, M.d., Ph.d, M.D., PH.D
Psychiatry — Payments: $90,000
Psychiatry $90,000